Navin Kapur, M.D., discusses the results of the FDA STEMI Door-to-Unloading (DTU) safety and feasibility randomized ...
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top detector detached and fell onto the detector below it. No patient injuries have been reported, although there remains a risk of potential life-threatening bodily harm if the detector were to detach and fall during a patient exam. The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall.
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) as a late-breaking abstract at the American Heart Association (AHA) Scientific Sessions 2018, Nov. 10-12 in Chicago. Results were simultaneously published in the New England Journal of Medicine (NEJM).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
James Januzzi, M.D., Hutter Family Professor at Harvard Medical School and a cardiologist at Mass General Hospital ...
Wilber Su, M.D., chief of cardiac electrophysiology, Banner University Medical Center, Phoenix, and clinical associate ...
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s (AHA) 2018 Scientific Sessions, Nov. 10-12 in Chicago. The second edition — announced at AHA by Adm. Brett P. Giroir, M.D., assistant secretary for health — provides evidence-based recommendations for youth ages three through 17 and adults to safely get the physical activity they need to stay healthy.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
James Januzzi, M.D., Hutter Family Professor at Harvard Medical School and a cardiologist at Mass General Hospital ...
Matthew Budoff, M.D., professor of medicine, David Geffen School of Medicine, UCLA, spoke at the 2018 American Heart ...
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Deepak L. Bhatt, M.D., executive director of the interventional cardiovascular program, Brigham and Women’s Hospital ...
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly reduced cardiovascular events, including cardiovascular death, in patients who continue to have high triglyceride levels on statin therapy. These findings could lead to a more effective and life-saving treatment option when used with other combinations of drugs to treat cardiovascular disease.
Black adults experience dangerous spikes in high blood pressure, called a hypertensive crisis, at a rate that is five times the national average, according to a new study. The study was presented at the American Heart Association’s (AHA) Joint Hypertension 2018 Scientific Sessions, an annual conference focused on recent advances in hypertension research, Sept. 6-9 in Chicago.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study for multi-access venous closure following electrophysiology (EP) procedures, according to manufacturer Cardiva Medical Inc. The AMBULATE study is the first randomized pivotal trial of vessel closure conducted exclusively by EP physicians.
At the American Heart Association’s (AHA) Scientific Sessions 2018, Nov. 10-12 in Chicago, Eko presented a clinical study abstract revealing the first murmur detection algorithm to outperform the majority of participating cardiologists. Entitled “Artificial Intelligence Detects Pediatric Heart Murmurs With Cardiologist-Level Accuracy,” the study demonstrates the power of machine learning and artificial intelligence (AI) to enhance cardiac care.
Wearable cardiac biosensor developer Cardiac Insight Inc. has partnered with VivoSense, specializing in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will deliver enhanced research analytics to help VivoSense expand the use of wearable biosensors for pharmaceutical clinical trials and other healthcare applications.